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Abstract
Background: Cardiac allograft rejection remains a significant clinical problem in the early phase
after heart transplantation and requires frequent surveillance with endomyocardial biopsy.
However, this is an invasive procedure, which is unpleasant for the patient and carries a certain
risk. Therefore, a sensitive non-invasive biomarker of acute rejection would be desirable.
Methods: Endomyocardial tissue samples and serum were obtained in connection with clinical
biopsies from twenty consecutive heart transplant patients followed for six months. A rejection
episode was observed in 14 patients (11 men and 3 women) and biopsies obtained before, during
and after the episode were identified. Endomyocardial RNA, from three patients, matching these
three points in time were analysed with DNA microarray. Genes showing up-regulation during
rejection followed by normalization after the rejection episode were evaluated further with real-
time RT-PCR. Finally, ELISA was performed to investigate whether change in gene-regulation
during graft rejection was reflected in altered concentrations of the encoded protein in serum.
Results: Three potential cardiac allograft rejection biomarker genes, chemokine (C-X-C motif)
ligand 9 (CXCL9), chemokine (C-X-C motif) ligand 10 (CXCL10) and Natriuretic peptide
precursor A (NPPA), from the DNA microarray analysis were selected for further evaluation.
CXCL9 was significantly upregulated during rejection (p < 0.05) and CXCL10 displayed a similar
pattern without reaching statistical significance. Serum levels of CXCL9 and CXCL10 were
measured by ELISA in samples from 10 patients before, during and after cardiac rejection. There
were no changes in CXCL9 and CXCL10 serum concentrations during cardiac rejection. Both
chemokines displayed large individual variations in the selected samples, but the serum levels
between the two chemokines correlated (p < 0.001).
Conclusion: We conclude, that despite a distinct up-regulation of CXCL9 mRNA in human hearts
during cardiac allograft rejection, this was not reflected in the serum levels of the encoded protein.
Thus, in contrast to previous suggestions, serum CXCL9 does not appear to be a promising serum
biomarker for cardiac allograft rejection.
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Background
Accumulating knowledge in the field of heart transplanta-
tion has led to improved patient survival and quality of
life. Cardiac allograft rejection, however, continues to
cause significant morbidity in the early phase after trans-
plantation and the detection of acute rejection remains an
important feature of transplant management.
The most common and reliable technique to evaluate
allograft rejection is endomyocardial biopsy [1]. How-
ever, the invasive nature of the procedure is inconvenient
for the patient and carries a risk for complications. These
drawbacks, along with a high cost, limit the use of
endomyocardial biopsy for frequent monitoring of car-
diac status after transplantation. Evidently, a sensitive
less-invasive technique for this purpose would be of
value.
Several non-invasive methods have been studied as a tool
for detecting allograft rejection, including echocardiogra-
phy, electrophysiology, cytoimmunologic monitoring,
radioisotopic techniques and magnetic resonance imag-
ing (reviewed by Kemke et al [2]). Also various biochem-
ical markers, such as neopterines [3], prolactin [4],
urinary polyamines [5], beta 2-microglobulins [6] and
brain natriuretic peptide (BNP) [7] have been suggested
for this purpose. However, none of the above methods or
markers has proven sensitive or specific enough to replace
endomyocardial biopsy [8].
DNA microarray gene expression analysis and other novel
technologies allowing high throughput analysis of thou-
sands of genes are today frequently used in experimental
biological studies. These techniques are more and more
often being used in the study of human disease using
human biopsy materials. For instance, DNA microarray
have been used in the search for genes with altered gene
expression in patients with prostate cancer [9], steatohep-
atitis [10] and leukaemia [11]. DNA microarray analysis
of human heart biopsies have previously been used to
investigate various heart diseases, e.g. tetralogy of Fallot
[12] and atrial fibrillation [13]. The utilization of such
techniques in the study of human cardiac allogaraft rejec-
tion may lead to the development of new biomarkers or
novel therapies of value in monitoring and treatment.
The aim of the present study was to utilize DNA microar-
ray analysis to search for potential biomarkers of cardiac
allograft rejection.
Methods
Patients and biopsies
Twenty consecutive patients undergoing orthotopic heart
transplantation between June 2002 and November 2003
were recruited and followed for 6 months. Immunosup-
pressive treatment included cytolytic induction therapy
followed by a triple-drug maintenance regimen with
cyclosporine or tacrolimus, azathioprine or mycophen-
alate mofetil and corticosteroids.
Routine endomyocardial biopsies were performed accord-
ing to the following schedule: weekly during the first six
weeks, every other week from week 6 to month 3 and
monthly from month 3 to month 6. Biopsies were exam-
ined by experienced pathologists and graded according
the 1990 working formulation of the International Soci-
ety of Heart and Lung Transplantation(ISHLT) [1]. Acute
cellular rejection grade 3A or higher was treated with
Methylprednisolon 1 g IV daily for three days and fol-
lowed up with a control biopsy 2 weeks later.
In connection with all clinical biopsies performed during
the study period, two additional myocardial specimens
were obtained and frozen in liquid nitrogen. At the same
time, blood samples were drawn and centrifuged. Tissue
samples and serum were stored at -70°C until analysis.
Episodes of rejection grade 2 or higher were identified, as
well as biopsies showing grade 0 closest in time before
and after each rejection. Myocardial tissue and serum
samples matching these three points in time were used for
analysis. In this way we defined a histopathological
sequence starting with a biopsy with normal histology
(before sample), followed by a rejection episode (during
sample) and finally a biopsy with normal histology after
the rejection episode (after sample).
The present study was approved by the regional ethics
committee at Göteborg University and performed accord-
ing to the declaration of Helsinki. All study subjects pro-
vided written informed consent.
RNA isolation
RNA isolation was performed from the endomyocardial
biopsies using the Chomczynski method [14] with a
minor modification: during the chloroform/phenol
extraction phase-lock gel tubes were used following the
manufactures instructions (Eppendorf INC., Hamburg,
Germany) followed by RNeasy clean-up protocol (Qia-
gen, Hilden, Germany). The quality of the RNA was veri-
fied by agarose gel electrophoresis before reverse
transcribed into cDNA.
DNA microarray analysis
Preparation of cRNA and hybridization to DNA microar-
rays was performed according to the Affymetrix Gene
Chip Expression Analysis manual. Briefly, RNA was
reversely transcribed into cDNA, biotin-labeled target
cRNA was prepared by in vitro transcription (Enzo Diag-
nostics Inc, Farmingdale, NY) followed by hybridizationBMC Cardiovascular Disorders 2006, 6:29 http://www.biomedcentral.com/1471-2261/6/29
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to DNA microarrays, Human Genome U133A arrays,
(Affymetrix, Santa Clara, CA, USA). The HU133A arrays
are composed of 22.283 probe sets i.e. 12 to 16 pairs of
25-mer oligonucleotides per probe set, representing
approximately 14.500 known human expressed genes.
The DNA microarrays were scanned with Hewlett Packard
confocal laser scanner (Hewlett Packard, GeneArray scan-
ner G2500A).
Data analysis
The mean target signal on each microarray was globally
scaled to an average intensity of 100. Scanned output files
were analyzed using Affymetrix Microarray Suite Version
5.0 software and Data Mining Tool 2.0 (Affymetrix, Santa
Clara, CA, USA). An average signal for the three time
points of the histopathological sequence (before, during
and after rejection) was calculated from the DNA microar-
rays from the three different subjects analysed. The aver-
age signal values were subjected to cluster analysis using
the self-organizing map (SOM) algorithm in the data
mining tool software (DMT; Affymetrix). The inclusion
filters for the clustering were a minimal average signal of
200 in at least one of the time points, a minimal fold
change of 1.6 between at least two of the time points and
a minimal maximum-minimum difference of 200
between at least two of the time points. A total of 102
genes were clustered into nine different clusters. More
detailed description of the clustering parameters used in
this experiment is presented as an additional file (see
Additional file: 1). Genes were classified as detectable
using the detection call algorithm. Any gene not display-
ing a present call (detectable) in all three subjects in at
least one of the time points were omitted from the analy-
sis. The identities, GeneOntology (GO) classification and
function of the cluster members were investigated using
the Netaffx database [15]. Tissue distribution of gene
expression was analyses using the SymAtlas database [16].
Selection of reference gene for real-time RT-PCR
The DNA microarray data was used to identify suitable ref-
erence gene for the real-time RT-PCR analysis. All probe
sets for four commonly used reference genes peptidylpro-
lyl isomerase A (cyclophilin A; PPIA), glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), actin beta (ACTB)
and ribosomal protein, large, P0 (RPLP0), were identified
using the Netaffx database. An average CV and signal
ratios were calculated for the probe sets.
Real time RT-PCR analysis
Reagents (TaqMan®  Reverse Transcriptase reagents and
TaqMan® Universal PCR Master mix) were purchased from
Applied Biosystems (Foster City, CA). cDNA was synthe-
sized with reverse transcriptase (RT) from RNA samples
using random hexamers as primers. Assay-on-demand
probes and primers for CXCL9 (Hs00171065_m1),
CXCL10 (Hs00171042_m1), and NPPA
(Hs00383236_g1) were purchased from Applied Biosys-
tems. Conditions were used according to the manufac-
turer's protocol. Real time RT-PCR analysis was performed
essentially as previously described [17]. In brief, amplifi-
cation and detection of specific products was performed
with the ABI Prism 7900 sequence detection system
(Applied Biosystems) using default cycle parameters. A
standard curve was plotted for each primer-probe set with
a serial dilution of pooled heart cDNA in the range of
0.156 ng to 40 ng original RNA per reaction. Assay-on-
demand probes and primers for human PPIA (Cyclophil-
lin A; Hs99999904_m1) was obtained from Applied Bio-
systems and used as reference to normalize the expression
levels between the samples. Genexpression of CXCL9,
CXCL10 and NPPA were analysed in samples obtained
from eight patients before, during and after cardiac rejec-
tion. All standards and samples were analyzed in tripli-
cate.
Serum analysis
Serum concentrations of CXCL9 and CXCL10 were deter-
mined using Quantakine ELISA kits (R&D Systems Europe
Ltd., Abingdon, UK) according to the manufacturer's
instructions. CRP (Latex) was determined using Tina-
quant C-reactive protein high sensitive assay (HS no
1972944001; Roche Diagnostics) according to the manu-
facturer's instructions. Serum concentrations of CXCL9
and CXCL10 were analysed in samples obtained from 12
patients before, during and after cardiac rejection. All
standards and samples were analyzed in duplicates.
Statistical analysis
Statistical analysis was performed by ANOVA and Spear-
man's correlations using the AnalyzeIt 1.71 software
(AnlyzeIt software Ltd, Leeds, England).
Results
Subjects with acute cardiac allograft rejection
A rejection episode, ISHLT grade 2 or higher, which was
considered suitable for analysis, was identified in 14
patients (Table 1). This group consisted of 11 males and 3
females, with a mean age of 54 years. The patients had
been referred to transplantation with the following diag-
noses: dilated cardiomyopathy (n = 9), ischemic cardio-
myopathy (n = 4) and hypertrophic cardiomyopathy (n =
1). The median time from transplantation to rejection was
55 days (range 20 to 104 days).
Overall analysis of DNA microarray data
The DNA microarray analysis of endomyocardial tissue
showed that approximately 44.5% (range 47% to 41%) of
the genes on the DNA microarray were detectable, and a
total 102 genes were defined as regulated. The raw data of
the DNA microarray analysis can be found at the GeneBMC Cardiovascular Disorders 2006, 6:29 http://www.biomedcentral.com/1471-2261/6/29
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expression omnibus (GEO) database (GSE4315) [18]. A
self-organizing map (SOM) cluster analysis was used to
classify regulated genes into 9 different clusters. Clusters
number 5 contained no genes, whereas the remaining
clusters contained between 2 and 22 genes (Figure. 1).
Analysis of gene clusters
The genes of cluster three displayed a pattern likely to con-
tain possible rejection markers (Figure 1). Cluster 3 con-
tained 16 genes that were activated during rejection and
returned to baseline levels after rejection (Table 2). Three
genes from this cluster, chemokine (C-X-C motif) ligand
9 (CXCL9), chemokine (C-X-C motif) ligand 10
(CXCL10) and natriuretic peptide precursor A (NPPA)
were selected for further evaluation based on their magni-
tude of activation (19-fold, 5-fold and 2.6-fold, respec-
tively) and the fact that they encode secreted proteins/
peptides (Table 2). All of the genes in cluster 3 were clas-
sified as detectable by the detection call algorithm. Also
clusters 1, 2, 8 and 9 displayed an expression pattern indi-
cating that they may contain possible rejection markers
(Figure 1). However, these clusters contained few genes
encoding secreted products and no genes from these clus-
ters were selected for further evaluation (see Additional
file 2).
Identification of reference gene for real time RT-PCR 
analysis
Most mRNA quantification methods rely on the use of ref-
erence genes to normalize assay variability. We used a glo-
bal scaling approach for the normalization of DNA
microarray data (all probes on the array was used for the
array-to-array normalization). Therefore, it is possible to
use Affymetrix DNA microarray data to identify genes that
are stably expressed and can be used as reference genes for
other mRNA quantification methods [19]. Probe sets for
four commonly used reference genes (GAPD, ACTB,
RPLP0 and PPIA) were identified using the Netaffx data-
base. PPIA was selected as reference gene for the real-time
RT-PCR analysis based on its low average CV value (>10
%) and low between group variability (>10 %).
Real-time RT-PCR analysis
Three genes from cluster 3, CXCL9, CXCL10 and NPPA,
were selected for verification by real time PCR. The analy-
sis was performed on samples from eight patients before,
during and after rejection. The expression of CXCL9 was
significantly up-regulated during rejection compared to
both before and after rejection (Figure 2A; p < 0.05 and p
< 0.05, respectively). The expression pattern of CXCL10
was similar to CXCL9, but the change was not significant
(Figure 2B). NPPA gene expression was elevated both dur-
ing and after rejection compared to the before rejection
samples, however the change was not significant (Figure
2C).
Serum analysis of CXCL9 and CXCL10 concentrations
Several studies have demonstrated that chemokines par-
ticipate in the inflammatory response within the human
transplanted heart [20,21]. Based on this and the results
from the real-time RT-PCR analysis, the serum levels of
CXCL9 and CXCL10 were measured by ELISA in serum
Table 1: Characteristics of the patients in the study. The characteristics of the patients and the different analysis performed on 
samples from the patients in this study. The mean age in years and the mean time from transplantation to rejection in days are shown. 
DNA microarray and real time RT-PCR analysis was performed on RNA from endomyocardial biopsies and ELISA analysis was 
performed on serum samples. * DCM = dilated cardiomyopathy, ICM = ischemic cardiomyopathy, HCM = hypertrophic 
cardiomyopathy.
Patient Diagnosis* Sex Age (y) Rejection Time (d) ISHLT Analysis
Array PCR ELISA
1 DCM M 58 104 3A X
4 D C M F 4 89 13 X
5 D C M F 3 83 72 X
6I C M M 6 6 7 4 3 A X X
7 DCM M 56 60 3A X X
8 DCM M 60 77 3B X X
9 D C M M 5 85 72 X
10 ICM M 59 14 3A X X
11 ICM M 63 55 3A X
12 HCM M 59 21 3A X X
13 DCM F 37 17 3B X X
15 ICM M 67 23 3A X X
16 DCM M 33 55 3A X X
20 DCM M 53 20 3A X X
Mean 54 55BMC Cardiovascular Disorders 2006, 6:29 http://www.biomedcentral.com/1471-2261/6/29
Page 5 of 10
(page number not for citation purposes)
samples from 10 patients before, during and after rejec-
tion. There were no changes in CXCL9 and CXCL10 serum
concentrations during rejection (Figure 3A and 3B). Both
these chemokines displayed large individual variations in
the selected samples. However, the serum levels of these
two factors correlated (Figure 4A; p < 0.001) but they did
Cluster analysis of DNA microarray data from samples before, during and after cardiac rejection Figure 1
Cluster analysis of DNA microarray data from samples before, during and after cardiac rejection. Cluster analy-
sis of DNA microarray data from endomyocardial biopsie samples from three subjects before, during and after cardiac rejec-
tion. Nine clusters were generated by SOM clustering containing 0–22 genes. The mean profile of the cluster members are 
indicated by solid lines and the dashed lines indicate standard deviation. The number of cluster members is indicated within 
parenthesis. Circles indicate the analysed time-points in the histopathological sequence (before, during and after rejection).
Cluster 1 (16)
Cluster 4 (6)
Cluster 7 (9) Cluster 8 (9) Cluster 9 (22)
Cluster 5 (0) Cluster 6 (2)
Cluster 3 (16) Cluster 2 (22)
Before During After Before During After Before During AfterBMC Cardiovascular Disorders 2006, 6:29 http://www.biomedcentral.com/1471-2261/6/29
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Real-time RT-PCR analysis of gene expression before, during and after cardiac rejection Figure 2
Real-time RT-PCR analysis of gene expression before, during and after cardiac rejection. The gene expression lev-
els of CXCL9 (A), CXCL10 (B) and NPPA (C) in endomyocardial biopsies was determined in eight subjects using real-time RT-
PCR. The different time-points in the histopathological sequence (before, during and after rejection) are indicated. Gene 
expression levels were relative to the reference gene peptidylprolyl isomerase A (PPIA). The results are presented as mean ± 
SEM. *: p < 0.05 (ANOVA).
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Table 2: Genes included in cluster 3. Genes are presented by their Affymetrix identification code (Affy ID), gene name, gene symbol 
and GO cellular component classification. The mean signals from the DNA microarray analysis from the three patients during the 
time-points in thehistopathological sequence (before, during and after rejection) are presented. Two probe sets detecting the STAT1 
and HLA-C genes are included in the cluster.
Affy ID Gene name Gene symbol GO cell 
component
Mean microarray signal
Before During After
200887_s_at Signal transducer and activator of transcription 1, 91 
kDa
STAT1 Nucleus, 
cytoplasm
723 1185 719
201508_at Insulin-like growth factor binding protein 4 IGFBP4 Extracellular 352 664 407
201762_s_at Proteasome (prosome, macropain) activator subunit 2 
(PA28 beta)
PSME2 Proteasome 
activator complex
370 598 424
202269_x_at Guanylate binding protein 1, interferon-inducible, 67 
kDa
GBP1 ---- 224 438 237
203915_at Chemokine (C-X-C motif) ligand 9 CXCL9 Extracellular 57 1106 250
204070_at Retinoic acid receptor responder (tazarotene induced) 
3
RARRES3 ---- 122 425 175
204533_at Chemokine (C-X-C motif) ligand 10 CXCL10 Extracellular 103 589 184
204806_x_at Major histocompatibility complex, class I, F HLA-F ---- 530 1040 634
208451_s_at Complement component 4A C4A Extracellular 260 589 295
209957_s_at Natriuretic peptide precursor A NPPA Extracellular 1041 2780 1024
211799_x_at Major histocompatibility complex, class I, C HLA-C Integral to 
membrane
301 670 372
214459_x_at Major histocompatibility complex, class I, C HLA-C Integral to 
membrane
2157 3655 2553
216187_x_at Homo sapiens Alu repeat (LNX1) mRNA sequence ---- ---- 472 832 551
217436_x_at Major histocompatibility complex, class I, J HLA-J Integral to 
membrane
231 517 299
217767_at Complement component 3 C3 Extracellular 338 531 310
HUM-ISGF3A_3_at Signal transducer and activator of transcription 1, 91 
kDa
STAT1 Nucleus, 
cytoplasm
390 665 357BMC Cardiovascular Disorders 2006, 6:29 http://www.biomedcentral.com/1471-2261/6/29
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ot correlate with serum high sensitive C-reactive protein
(hsCRP, Figure 4B and 4C), (a general marker systemic
inflammatory status; data not shown).
Discussion
Allograft rejection remains a significant clinical problem
in the first year after heart transplantation. Endomyocar-
dial biopsy has been the most reliable method to detect
rejection, but is invasive, causes discomfort to the patient
and is resource demanding. Furthermore, artefacts and
inter-observer variability may cause difficulties in his-
topathological interpretation. Several attempts have been
made to identify a reliable non-invasive test for cardiac
rejection, but, so far, the search for such a marker has been
unsuccessful.
Despite intensive research, the mechanisms involved in
organ allograft rejection, are largely unclear. DNA micro-
array experiments to identify mechanisms involved in car-
diac rejection have previously been performed in animal
models. Stegall et al have used DNA microarray analysis to
study the Brown Norway to Lewis heterotopic heart trans-
plant model [22]. Although many of the up-regulated
genes in their study were associated with the inflamma-
tory process, no data on the regulation of CXCL9 and
CXCL10 are presented. They report an up regulation of
Allograft inflammatory factor-1 (AIF1) during all of the
investigated time point (3, 5 and 7 days) after heart trans-
plantation. In our study, gene expression of AIF1 was not
detectable in any of the time points investigated. Saiura et
al  has used DNA microarray analysis to investigate a
mouse model of cardiac rejection. They showed that inter-
feron (IFN)-gamma plays a central role in acutely rejected
grafts by inducing several chemokines [23] and that IFN-
gamma deficient mice do not have an increased expres-
sion of CXCL9 and CXCL10 during the rejection process.
They also show that gene expression of macrophage
inflammatory protein 1 alpha (Mip1 alpha) is increased
during the rejection process both in IFN-gamma deficient
and in wile type mice. However, in our study the gene
expression of the human Mip1 alpha homolog (chemok-
ine C-C motif ligand 3; CCL3) was not detectable in any
of the time points investigated. The above animal models
may not be representative for human heart transplants,
Analysis of chemokine serum levels before, during and after cardiac rejection Figure 3
Analysis of chemokine serum levels before, during and after cardiac rejection. Concentrations of CXCL9 (A) and 
CXCL10 (B) were determined by ELISA in serum samples from twelve subjects (each represented as one line in the graph). 
The different time-points in the histopathological sequence (before, during and after rejection) are indicated. The results are 
presented as mean chemokine concentrations.
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but differences in gene expression patterns compared to
our study may also be due to differences in the DNA
microarrays used and/or the time points analysed.
The expression and role of CXCL9 and CXCL10 during
cardiac rejection has previously been investigated both in
experimental models [23-26] and in humans [20,21].
Kapoor et al has shown, in a mouse model, that the
expression of CXCL9 and CXCL10 is dramatically
increased during cardiac rejection and dependent upon
CD8+ T cells of the recipient [24]. Similar findings have
been reported by Carvalho-Gaspar et al [27]. Zhao et al
showed that the expression both of CXCL9 and CXCL10
are elevated in human hearts during rejection and that the
two chemokines have a differential cellular distribution in
the rejecting heart. It was also proposed that the chemok-
ine pathway might serve as a useful monitor for the treat-
ment and prevention of cardiac rejection.
The activation of myocardial CXCL9 during the rejection
process in human heart transplants, observed in the
present study, is in line with previous reports. CXCL10
displayed a similar pattern, which did not reach statistical
significance; possibly due to our small sample size. To fur-
ther evaluate the potentiality of these chemokines as use-
ful non-invasive biomarkers, we measured corresponding
serum levels before, during and after rejection. Despite the
cardiac activation of CXCL9 and CXCL10 gene expression
during rejection, this was not reflected in serum levels of
the encoded proteins, On the contrary, a large inter- and
intra-individual variation was observed, suggesting that
mechanisms other than the rejection process are of impor-
tance with respect levels of these chemokines in serum.
Thus, our findings do not support the usefulness of CXL9
and CXCL10 as non-invasive markers of cardiac rejection
Cardiac natriuretic peptides, atrial natriuretic factor (ANF)
and brain natriuretic peptide (BNP) have also been pro-
posed as a potential biomarkers of cardiac allograft rejec-
tion. Previous studies have shown that serum BNP tends
to increase during allograft rejection and decline follow-
ing treatment [, , ], but these patterns have not proven suf-
ficiently predictive to be clinically useful. Although the
present microarray analysis indicated a moderate up-reg-
ulation of NPPA during rejection, this could not be con-
firmed with real time PCR. These negative findings could
be explained by a small sample size and low statistical
power. Furthermore, previous studies have observed a
non-specific activation of natriuretic peptides up to 6
months post-transplant [], which might obscure the rela-
tionship with early rejections.
Several markers are known to represent the systemic
inflammatory status, including CRP. The CRP serum lev-
els also displayed high variability, but did not correlate to
serum CXCL9 or CXCL10 levels. This indicates that sys-
temic inflammatory status of the patient does not directly
contribute to CXCL9 and CXCL10 serum levels. A success-
Correlation between the serum concentrations of CXCL9, CXCL10 and hsCRP Figure 4
Correlation between the serum concentrations of CXCL9, CXCL10 and hsCRP. Concentrations of CXCL9, 
CXCL10 and hsCRP were determined by ELISA in serum samples from twelve subjects at different time-points in the his-
topathological sequence (before, during and after rejection) Correlations between CXCL9 and CXCL10 (A), CXCL9 and 
hsCRP (B) and CXCL10 and hsCRP (C).
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ful cardiac rejection biomarker should not only be specific
to the rejection process, but also, have a limited tissue dis-
tribution profile. Bioinformatical analysis of the mRNA
tissue distribution (SymAtlas database) shows that,
whereas NPPA is specifically expressed in heart tissue,
CXCL9 and CXCL10 are more generally expressed and
may therefore be less suitable as serum markers of rejec-
tion.
The lack of success in the identification of cardiac rejec-
tion biomarkers in the current study indicate that expres-
sion profiling of immunological active cells of the heart
recipient may be a better way to identify cardiac rejection
biomarkers.
Conclusion
We conclude that CXCL9 mRNA is upregulated in human
hearts during rejection. However, this was not reflected in
serum levels of the encoded protein. Contrary to previous
suggestions [18], this indicates that CXCL9 and CXCL10
are not promising serum biomarker for this condition.
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